Navigation Links
Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
Date:10/3/2007

ation of escalating doses of TPI 287 and temozolomide, both orally administered, in tumors of the central nervous system.

At the meeting of the American Society of Clinical Oncology in June 2007, the Company reported interim data from two Phase 1 studies, each evaluating a different dosing regimen for the compound. The data demonstrated the safety and tolerability of TPI 287 in both schedules, and included evidence of anti- tumor activity in four patients at or near the maximum tolerated dose in three different tumor types.

About Pancreatic Cancer

Pancreatic cancer is a tumor that forms in the pancreas, a small, thin gland located behind other organs in the abdomen. Pancreatic cancer is difficult to detect and diagnose due to a lack of noticeable symptoms of the disease in its early stages. For newly diagnosed patients who are eligible for surgical treatment of the disease, surgery is typically followed by a combination of radiation and chemotherapy. Patients whose disease has become inoperable because of extensive local spread of the disease receive a combination of radiation and chemotherapy. Advanced stage patients with more widespread or metastatic disease are generally treated with chemotherapy alone. In patients with inoperable cancer, therapy is only palliative, which means that it only slows the disease's progress rather than providing a cure. Gemcitabine is approved as the initial chemotherapy for patients with inoperable pancreatic cancer. Other drugs are only marginally effective, including fluoropyrimidine and Tarceva (erlotinib).

About TPI 287

TPI 287, a proprietary next-generation taxane, is Tapestry's lead clinical compound. This compound was designed to overcome multiple drug resistance in solid tumors that are innately resistant to taxane therapy or have become resistant to taxanes following exposure to chemotherapy drugs. In preclinical testing, TPI 287 demonstrated the ability to inhibit tumor cell growth in a number
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Calif. , Oct. 22, 2014  AcelRx ... announced that results from the  IAP310 study have ... Medicine (RAPM), a peer-reviewed journal with broad, ... 3 trial evaluating the safety and efficacy of ... tablet system (SSTS), for the treatment of post-operative ...
(Date:10/20/2014)... , 20 de octubre de 2014 /PRNewswire/ ... el campo de la pulmonología intervencional, anunció hoy ... RENEW, casi 3 meses antes de lo programado. El ... exención de dispositivo de investigación (IDE) aprobada por ... el sistema de espiral de reducción de volumen ...
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014   BioNano ... the Irys system: the ability to collect human data at ... on a single chip.  This new capability was established and ... for the Irys TM System and will ... next two months. BioNano will be showcasing this advancement at ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... 26, 2012 Interventional Spine, Inc. today announced ... Body Fusion Device. (Logo: ... Access Instrument, which provides unparalleled percutaneous access to ... an integral part of Interventional Spine,s revolutionary PerX360 ...
... VIEW, Calif., Jan. 25, 2012  IRIDEX Corporation (Nasdaq: ... clinical study evaluating the use of IRIDEX, MicroPulse ... effectiveness with patients diagnosed with central serous chorioretinopathy ... is superior to anti-VEGF injections for CSC, also ...
Cached Medicine Technology:Interventional Spine, Inc. Announces FDA Clearance of its Opticage™ Expandable Interbody for Treatment of Degenerative Disc Disease 2IRIDEX MicroPulse™ Laser Therapy Enhances Visual Function in Patients with Central Serous Chorioretinopathy (CSC) 2IRIDEX MicroPulse™ Laser Therapy Enhances Visual Function in Patients with Central Serous Chorioretinopathy (CSC) 3
(Date:10/22/2014)... 2014 During the Western United States’ ... runs dangerously low, Southern Oregon’s water is proving resistant ... the lowest mountain snow pack on record in 2014, ... early autumn.* That was the observation of journalist-hikers Art ... “Hiking Southern Oregon,” during an interview with water advocate ...
(Date:10/22/2014)... October 22, 2014 Healthcare professionals ... their continuing education at home or on-the-go via ... to 20 brand new, premium Seminar-on-Demand CE courses. ... of over 2,000 hours of CE ... their educational experience. With such a diverse library, ...
(Date:10/22/2014)... 22, 2014 Although there are only 24 hours ... many people who have trouble finding time within their busy schedules ... for long periods of time to get in shape. Here are ... on the go. , Change Up Your Commute , Consider ... to add some exercise into your daily routine. If you must ...
(Date:10/22/2014)... October 22, 2014 Richard Carlson, Managing ... industry leader with over 25 years experience. Mr. ... in the areas related to EDI, B2B Commerce, RFID ... an Editorial Advisory Board member for Pharmaceutical Commerce Magazine ... Blue Fin Group is a management and technology consulting ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... length may be showing a genetic propensity for obesity as ... have been linked to increased body fat, but the same ... muscle, the researchers said. At 1 year, kids with ... and 3, however, these genes were linked to excessive weight ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... LAKE CITY University of Utah researchers have developed an ... phones or sending text messages while driving. , The university ... to a private company that hopes to see it ... less than $50 per key plus a yet-undetermined monthly service ...
... Dec. 10 PADRES Contra El Cancer, an,organization dedicated ... cancer and their families, will host its Annual Holiday ... 2008. , Children ... playing,and sledding amongst 40 tons of snow while enjoying ...
... City , , ATLANTIC CITY, N.J., Dec. ... been wounded in the Iraq conflict and recuperating at Walter Reed Army ... to Harrah,s Resorts in Atlantic City. , , ... , from war injuries and wishing for the chance to ...
... Medical Systems (NYSE: VAR ) announced today that it ... the close of regular trading on Thursday, January 29, 2009. ... all interested parties at 2:00 p.m. PT. , ... accessed on January 29, 2009. The news release and information on ...
... Dec. 10 Basic government services are not being provided ... and other communicable diseases are rampant. Staggering inflation and unemployment ... that 300,000 people remain at risk of cholera, which is ... lack of functioning sanitation services. To date, the outbreak has ...
... wait longer for ER treatment, elective procedures, study says ... be a shortage of 1,300 general surgeons in the ... shortage could increase to 6,000 by 2050, a new ... perform lifesaving operations on critically injured or seriously ill ...
Cached Medicine News:Health News:Car key jams teen drivers' cell phones 2Health News:Car key jams teen drivers' cell phones 3Health News:Car key jams teen drivers' cell phones 4Health News:PADRES Contra El Cancer to Host its 10th Annual Posada Holiday Celebration for Children with Cancer 2Health News:Wounded Warriors to be Holiday Guests of Harrah's Entertainment 2Health News:Varian Medical Systems Schedules First Quarter FY2009 News Release and Conference Call 2Health News:Varian Medical Systems Schedules First Quarter FY2009 News Release and Conference Call 3Health News:U.S. May Soon Face Shortage of General Surgeons 2